Levonadifloxacin in deranged creatinine
Reading File
Searching the Web
levonadifloxacin dose adjustment renal impairment creatinine clearance
Searching PubMed
levonadifloxacin renal impairment pharmacokinetics
Reading Web Page
https://emrok.co.in/Prescribing-Information.html
Finding Sources
Here is a complete, evidence-based answer on levonadifloxacin in the setting of deranged creatinine/renal impairment:
Levonadifloxacin in Renal Impairment
The Key Fact
No pharmacokinetic (PK) studies have been conducted in renally impaired patients for levonadifloxacin (Emrok IV / Emrok O oral). This is explicitly stated in the official prescribing information from Wockhardt (the manufacturer of Emrok) for both the IV and oral formulations.
This means there is no manufacturer-recommended dose adjustment table for CrCl or eGFR cutoffs - unlike levofloxacin, which has a well-established renal dose adjustment schedule.
Why This Matters Pharmacokinetically
Understanding the elimination profile helps explain the clinical risk:
| Parameter | Value |
|---|---|
| Elimination half-life (IV, multiple doses) | ~6.8 hours |
| Serum clearance | ~4.2 L/h |
| Renal excretion - unchanged drug | ~2.3% in urine |
| Renal excretion - sulphate metabolite | ~50.3% in urine |
| Total urinary recovery (parent + metabolite) | ~52.6% |
The active sulphate metabolite (levonadifloxacin sulphate) is excreted predominantly in urine (~50.3%). In renal impairment, this metabolite may accumulate. The parent drug itself has minimal direct renal excretion (~2.3%), which is actually quite different from levofloxacin (where ~85% is renally cleared as unchanged drug).
Practical Clinical Guidance
Because formal renal impairment PK data are absent, clinicians must exercise caution based on the available metabolite excretion data:
-
Mild-to-moderate renal impairment (CrCl 30-60 mL/min): No specific dose adjustment is officially recommended, but monitoring is prudent given the sulphate metabolite's high urinary excretion.
-
Severe renal impairment (CrCl <30 mL/min) / ESRD / dialysis: No data are available. Use with caution or avoid. The sulphate metabolite accumulation risk is real but unquantified. Manufacturer guidance is silent here.
-
No accumulation was observed in normal-renal-function subjects over 5 days of multiple dosing - this is reassuring for patients with intact renal function.
Comparison with Levofloxacin (for context)
Unlike levonadifloxacin, levofloxacin (~85% renally excreted unchanged) has well-characterized dose adjustments:
- CrCl 20-49 mL/min: 750 mg every 48 h (or 500 mg q24h reduced to 250 mg q24h)
- CrCl 10-19 mL/min: Loading dose, then halved every 48 h
- Hemodialysis/CAPD: Same as CrCl 10-19 mL/min
Levonadifloxacin does NOT follow this same profile because it is largely metabolized and excreted as a sulphate conjugate rather than as unchanged drug.
Hepatic Impairment (for completeness)
Interestingly, hepatic PK studies were performed:
- Mild/moderate hepatic impairment (Child-Pugh A/B): No dose adjustment needed
- Severe hepatic impairment (Child-Pugh C): AUC increases ~1.69-1.7-fold - still <2-fold, so no dose adjustment is recommended, though caution is advised
Bottom Line
The prescribing information for levonadifloxacin (Emrok/Emrok O) states that PK studies in renal impairment have not been conducted, and provides no specific dose adjustment recommendations for any level of CrCl. Given that ~50% of the dose is recovered as the sulphate metabolite in urine, accumulation is theoretically possible in moderate-severe renal impairment. In patients with significantly deranged creatinine, the benefit-risk ratio should be carefully weighed, an infectious disease specialist should be involved, and the patient should be closely monitored for adverse effects (especially QT prolongation, tendinopathy, and CNS toxicity typical of fluoroquinolones).
Source: Emrok Official Prescribing Information (Wockhardt Ltd., India)
This is a shared conversation. Sign in to Orris to start your own chat.